When NewAmsterdam Pharma Co N.V. reports, what it reported each quarter, and how the stock took the results.
15 quarters. Mar 31, 2023 to Sep 30, 2026. USD.
Feb 17, before the open
Wed, Feb 17, 2027in 88 days
Projected from its last 8 releases. The company has not named the day yet.
| Period | Ended | Announced | Filed | Lag | Form | Revenue | Δ yoy | EPS dil. | Move | Source trail |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2026 | ||||||||||
| Q3 2026 | ||||||||||
NewAmsterdam Pharma Co N.V. · CIK 1936258 · Engraved from SEC EDGAR
| Sep 30, 2026 |
| — |
| Nov 4, 2026 |
| 35 d |
| 10-Q |
| $19.16M |
| +5,406.9% |
| -$0.14 |
| — |
| Q2 2026 | Jun 30, 2026 | Aug 5, 2026 · pre-market | Aug 5, 2026 | 36 d | 10-Q | $3.70M | −80.7% | -$0.52 | — |
|---|
| Q1 2026 | Mar 31, 2026 | May 7, 2026 · pre-market | May 7, 2026 | 37 d | 10-Q | $3.04M | +2.1% | -$0.40 | — |
|---|
| FY 2025 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2025derived | Dec 31, 2025 | Feb 18, 2026 · pre-market | Feb 18, 2026 | 49 d | 10-K | $32.00K | −99.7% | — | — | |
| Q3 2025 | Sep 30, 2025 | Nov 5, 2025 · pre-market | Nov 5, 2025 | 36 d | 10-Q | $348.00K | −98.8% | -$0.61 | — | |
| Q2 2025 | Jun 30, 2025 | Aug 6, 2025 · pre-market | Aug 6, 2025 | 37 d | 10-Q | $19.15M | +740.1% | -$0.15 | +12.6% | |
| Q1 2025 | Mar 31, 2025 | May 8, 2025 · pre-market | May 8, 2025 | 38 d | 10-Q | $2.98M | +112.6% | -$0.34 | — | |
| FY 2024 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2024derived | Dec 31, 2024 | Feb 26, 2025 · pre-market | Feb 26, 2025 | 57 d | 10-K | $12.77M | +1,490.5% | — | +32.0% | |
| Q3 2024 | Sep 30, 2024 | Nov 6, 2024 · pre-market | Nov 6, 2024 | 37 d | 10-Q | $29.11M | +889.8% | -$0.18 | +25.0% | |
| Q2 2024 | Jun 30, 2024 | Aug 7, 2024 · pre-market | Aug 7, 2024 | 38 d | 10-Q | $2.28M | +32.7% | -$0.41 | — | |
| Q1 2024 | Mar 31, 2024 | — | May 8, 2024 | 38 d | 10-Q | $1.40M | −83.8% | -$1.06 | — | |
| FY 2023 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2023derived | Dec 31, 2023 | Feb 28, 2024 · pre-market | Feb 28, 2024 | 59 d | 10-K | $803.00K | — | — | — | |
| Q3 2023 | Sep 30, 2023 | — | — | — | — | $2.94M | — | -$0.57 | — | |
| Q2 2023 | Jun 30, 2023 | — | — | — | — | $1.72M | — | -$0.47 | — | |
| Q1 2023 | Mar 31, 2023 | — | — | — | — | $8.63M | — | -$0.51 | — | |
Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.
Few filings are on file, so the projected window is widened until the pattern is clear.
The stock’s move from the last close before each release to the first close after it, over the last 3 releases. Largest: +32.0% after Q4 2024.
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.